An expanded lecture by Vitalii Radko, MD PhD, Head of Department at Mother and Child Medical Centre (Kyiv), on applying pharmacogenomics beyond FSH/LH receptors — in complex ART clinical cases. The 180-gene infertility panel, ESR1/ESR2 polymorphisms in oocyte donors (Belen Lledó, Bernabeu Institute), the ESR2 rs4986938 marker for idiopathic thin endometrium, poor blastulation in patients under 40 and calcium ionophore in a selected cohort, the WEE2 gene — recurrent ICSI fertilisation failures, true empty follicle syndrome via LHCGR and zona pellucida proteins ZP1-3.


MD, PhD
Head doctor at the «Mother and Child» Medical Center in Kyiv. Candidate of Medical Sciences (PhD), obstetrician-gynecologist, reproductive specialist and gynecologist-endocrinologist.
Pharmacogenomics in ART does not end at ovarian stimulation. The lecture shifts focus to embryology, the endometrium, and the cases where classical protocols fail for reasons hidden in the genome — from oocyte donors to total fertilization failure after ICSI.
ESR1 and ESR2 polymorphisms in patients and oocyte donors correlate with embryo quality and cycle clinical efficacy. A particular clinical interest is genetic predictors of idiopathic thin endometrium, which open a new diagnostic class for patients previously catalogued as «cause unknown».
Systematically poor blastulation in younger patients is a distinct clinical problem. Calcium ionophore has a role as targeted therapy — in a selected cohort where artificial activation compensates for insufficient calcium signalling after fusion. It is not a «universal solution». The literature is mixed: some studies show benefit in specific indications, others show no effect in general populations. The speaker's own pilot data support efficacy when poor blastulation is combined with ESR polymorphisms.
The WEE2 gene encodes a kinase required for exit from meiotic arrest after sperm entry. WEE2 mutations are one of the identified causes of total fertilization failure after ICSI when all other parameters are normal. In such patients, repeat ICSI without intervention is futile — the diagnosis redirects them toward oocyte donation or experimental approaches.
Empty follicle syndrome is a real genetic phenomenon, but it must be distinguished from a pseudo-form caused by clinical errors (incorrect trigger, timing, mismatched post-trigger marker assessment). Only the true syndrome is a genetic pathology. The LH/hCG receptor and zona pellucida proteins, critical for the fertilization process, play a role here. Differentiation allows for the correct strategy — from protocol correction to a change of clinical route.
Modern commercial panels cover about 180 infertility genes, a portion of which are already clinically validated. The approach is not «test everyone» but «select tests by clear clinical triggers»: failed ICSI, thin endometrium, poor blastulation, repeated embryo loss. A properly built pre-cycle workup turns «cause unknown» into a manageable clinical category.